Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 15Terminated 2Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Hairy Cell 1Intraocular Lymphoma 1Hodgkin Disease 1Enteropathy-Associated T-Cell Lymphoma 1Carcinoma, Ovarian Epithelial 1Burkitt Lymphoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 2Melphalan 2Etoposide 2Cytarabine 2Cyclophosphamide 2Carmustine 2tenalisib 1tazemetostat 1romidepsin 1fludarabine phosphate 1etoposide phosphate 1Whole-Body Irradiation 1Vorinostat 1Vincristine 1Transplantation 1Tacrolimus 1Prednisone 1Prednisolone 1O(6)-benzylguanine 1Mycophenolic Acid 1IMC-001 1E7777 fusion protein 1Doxorubicin 1Cord Blood Stem Cell Transplantation 1Bortezomib 14-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lymphoma, T-Cell, Peripheral × romidepsin × Clear all
NCT03355768 2018-12-19

Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL

Columbia University

Phase 3 Withdrawn
Lymphoid

Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡